title: Hydrocaffeic and p-coumaric acids, natural phenolic compounds, inhibit UV-B damage in WKD human conjunctival cells in vitro and rabbit eye in vivo.
abstract: This paper studied the effect on UV-B ocular damage of 10microM hydrocaffeic acid (HCAF) alone and as a mixture (MIX) (5 microM HCAF+5 microM p-coumaric acid). Since ocular UV-B damage is mediated by reactive oxygen species, the aim was to test if HCAF and MIX could reduce oxidation damage in human conjunctival cells (WKD) in vitro and in cornea and sclera of rabbits in vivo. After UVB irradiation (44 J/m(2)) of WKD cells, 8-oxodG levels in DNA were markedly increased and this effect was attenuated by HCAF and MIX. Rabbit eyes were treated by application of HCAF and MIX drops before UV-B exposure (79 J/m(2)). Corneal and scleral DNA oxidation damage, xanthine-oxidase (XO) activity and malondialdehyde levels (MDA) in corneal tissue and prostaglandin E(2) (PGE(2)) in the aqueous humour were reduced by HCAF alone and in combination with p-coumaric acid, showing their potential as a topical treatment against UV-B damage.
authors.affiliation: Department of Pharmacology, University of Florence, Florence, Italy. mar.larrosa@unifi.it
authors.forename: Mar
authors.initials: M
authors.lastname: Larrosa
authors.forename: Maura
authors.initials: M
authors.lastname: Lodovici
authors.forename: Lucia
authors.initials: L
authors.lastname: Morbidelli
authors.forename: Piero
authors.initials: P
authors.lastname: Dolara
mesh_terms: D000080242:8-Hydroxy-2'-Deoxyguanosine; D000287:Administration, Topical; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology*; D001082:Aqueous Humor / Q000187:drug effects / Q000378:metabolism / Q000528:radiation effects; D002109:Caffeic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D002478:Cells, Cultured; D003228:Conjunctiva / Q000187:drug effects / Q000378:metabolism / Q000528:radiation effects; D003315:Cornea / Q000187:drug effects / Q000378:metabolism / Q000528:radiation effects; D003373:Coumaric Acids / Q000008:administration & dosage / Q000494:pharmacology*; D004249:DNA Damage / Q000187:drug effects*; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000378:metabolism; D015232:Dinoprostone / Q000378:metabolism; D004307:Dose-Response Relationship, Radiation; D005123:Eye / Q000187:drug effects* / Q000378:metabolism / Q000528:radiation effects; D006801:Humans; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects* / Q000528:radiation effects; D011422:Propionates; D011817:Rabbits; D011837:Radiation-Protective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D012590:Sclera / Q000187:drug effects / Q000378:metabolism / Q000528:radiation effects; D013997:Time Factors; D014466:Ultraviolet Rays; D014969:Xanthine Oxidase / Q000378:metabolism
chemical_list: D000975:Antioxidants; D002109:Caffeic Acids; D003373:Coumaric Acids; D011422:Propionates; D011837:Radiation-Protective Agents; D008315:Malondialdehyde; D000080242:8-Hydroxy-2'-Deoxyguanosine; D014969:Xanthine Oxidase; D003849:Deoxyguanosine; C495469:p-coumaric acid; D015232:Dinoprostone; C040048:caffeic acid